U-01

N/A

Report date: 2025/06/09 15:01:42

Base Information

Drug NameU-01
Drug Alias NameAutologous anti-CD19 CAR-T cells expressing a shRNA against IL-6白介素6分泌功能敲减的靶向CD19自体基因编辑T细胞注射液具有沉默白介素6表达功能的靶向CD19基因工程化自体T细胞注射液SsCART-19细胞疗法（优卡迪）ssCART-19 +[6] 
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionB-lymphocyte antigen CD19 modulatorsT lymphocyte replacements
TargetsB-lymphocyte antigen CD19
Therapy Area/IndicationsLymphoma, B-CellPrecursor B-Cell Lymphoblastic Leukemia-LymphomaPrecursor Cell Lymphoblastic Leukemia-Lymphoma +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesShanghai Unicar-Therapy Bio-Medicine Technology Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesShanghai Tongji HospitalShanghai Unicar-Therapy Bio-Medicine Technology Co Ltd
Inactive CompaniesN/A
Active IndicationsLymphoma, B-CellPrecursor B-Cell Lymphoblastic Leukemia-LymphomaPrecursor Cell Lymphoblastic Leukemia-Lymphoma +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A